Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

UCIdidmyDD Oct. 25 at 8:00 PM

$MSOS $VFF $TLRY $IGC for those of us crazy enough to accumulate shares, the 3-2-1…..crypto rally starts now… this will greatly improve liquidity for the hybrid cannacrypto investor. as for me, i do look forward to more liquidity…!!!

1 · Reply

1AMBITIOUSSAVAGE Oct. 25 at 3:37 PM

$IGC

0 · Reply

CarlSpagler Oct. 25 at 12:59 AM

$IGC they gonna let up keep loading under .42 for a while more ?

0 · Reply

IGC Oct. 24 at 7:33 PM

$IGC IGC Pharma was mentioned in Zacks Investment Research’s latest stock analysis. Read the full article here: https://finance.yahoo.com/news/strong-buy-stocks-oct-24-091700896.html . . . #InvestorRelations #FinanceNews #HealthcareInnovation #IGCPharma

0 · Reply

OffComesTheShirt Oct. 24 at 4:07 PM

$IGC 10% Off Comes The Shirt

1 · Reply

Clkrrb Oct. 24 at 3:53 PM

$IGC Come on Fifty Cents

0 · Reply

USA_toinfinity_andbeyond Oct. 24 at 3:41 PM

$IGC 🚀📈🇺🇸💰💲💯

0 · Reply

Marcobecco Oct. 24 at 3:14 PM

$IGC

0 · Reply

bongha Oct. 24 at 12:34 PM

$IGC

0 · Reply

Vote4Pedro2 Oct. 24 at 12:17 PM

$IGC

1 · Reply

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 11 days ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 15 days ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 18 days ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 26 days ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 6 weeks ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 3 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 4 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 4 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 5 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 5 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 6 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 6 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 7 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 7 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 9 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 9 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 10 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 10 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 11 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 11 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 11 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 1 year ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Oct 17, 2024, 8:30 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 3, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Sep 18, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 4, 2024, 8:00 AM EDT - 1 year ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 8, 2024, 9:30 PM EDT - 1 year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

UCIdidmyDD Oct. 25 at 8:00 PM

1 · Reply

1AMBITIOUSSAVAGE Oct. 25 at 3:37 PM

$IGC

0 · Reply

CarlSpagler Oct. 25 at 12:59 AM

$IGC they gonna let up keep loading under .42 for a while more ?

0 · Reply

IGC Oct. 24 at 7:33 PM

0 · Reply

OffComesTheShirt Oct. 24 at 4:07 PM

$IGC 10% Off Comes The Shirt

1 · Reply

Clkrrb Oct. 24 at 3:53 PM

$IGC Come on Fifty Cents

0 · Reply

USA_toinfinity_andbeyond Oct. 24 at 3:41 PM

$IGC 🚀📈🇺🇸💰💲💯

0 · Reply

Marcobecco Oct. 24 at 3:14 PM

$IGC

0 · Reply

bongha Oct. 24 at 12:34 PM

$IGC

0 · Reply

Vote4Pedro2 Oct. 24 at 12:17 PM

$IGC

1 · Reply

distanceswimmer Oct. 23 at 12:59 PM

$IGC developing a drug to lower anxiety and calm Alzheimer’s patients is a low bar for a cannabis drug formulation

0 · Reply

Whales22 Oct. 23 at 7:26 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $IGC $JBLU $USNA $RELY Watchlist

0 · Reply

IGC Oct. 22 at 3:27 PM

$IGC Innovation in Alzheimer’s research starts with rethinking how we use data. IGC Pharma’s AI-driven platform, AHA: Agentic Harmonization Assistant, has been recognized on the global stage—advancing to the semi-finals of the Alzheimer’s Insights AI Prize organized by the Alzheimer’s Disease Data Initiative (ADDI). By building on the foundation of MINT-AD, our deep-learning platform that unites complex clinical and biological information, we’re pushing the boundaries of what’s possible in Alzheimer’s drug discovery. For more information, please visit: https://bit.ly/47D7n9C #AlzheimersResearch #AIinHealthcare #HealthcareInnovation #Neuroscience #IGCPharma

0 · Reply

_AU79_ Oct. 22 at 3:08 PM

$BYND time for $IGC $TLRY $CGC ! IGC will be a monster!

0 · Reply

Vote4Pedro2 Oct. 22 at 2:05 PM

$BYND Next $IGC

0 · Reply

DiddyK0ng Oct. 22 at 11:13 AM

$IGC whats going on

1 · Reply

MK10 Oct. 21 at 7:59 PM

$IGC I'm working my way back to you, babe. With a burning love inside:)

0 · Reply

daytraderforplayandprofi Oct. 21 at 7:59 PM

$IGC I missed Qnccf for this. But I don’t regret being here. Excited for this to go too.

0 · Reply

_AU79_ Oct. 21 at 5:30 PM

$IGC is the next $BYND! IGC is a medical cannabis low floater play with history of major moves. Don’t be left out smart money is parking some cash here! Chart looks good. Squeeze to $12.00 is possible!

0 · Reply

Vote4Pedro2 Oct. 21 at 9:03 AM

$IGC We're ready

0 · Reply

VizTheWin Oct. 20 at 9:03 PM

$IGC ok

0 · Reply

USA_toinfinity_andbeyond Oct. 20 at 3:05 PM

$IGC Hype up!!🚀📈🇺🇸💰💲

0 · Reply

Market Cap	34.67M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	2,379,100
Avg Vol	987,674
Day's Range	N/A - N/A
Shares Out	91.96M
Stochastic %K	66%
Beta	1.04
Analysts	Strong Sell
Price Target	$3.75